1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
Diabetic Retinopathy Market Analysis Report By Type, By Management And Segment Forecasts, 2018 - 2025

Diabetic Retinopathy Market Analysis Report By Type, By Management And Segment Forecasts, 2018 - 2025

  • February 2018
  • 81 pages
  • ID: 5360516
  • Format: PDF
  • By Grand View Research

Summary

Table of Contents

Diabetic Retinopathy Market Analysis Report By Type (Proliferative DR, Non-Proliferative DR), By Management (Anti-VEGF Therapy, Intraocular Steroid Injection, Laser Surgery, Vitrectomy), And Segment Forecasts, 2018 - 2025

The global diabetic retinopathy market is anticipated to reach USD 10.08 billion by 2025, according to a new report by Grand View Research, Inc. Rising prevalence of diabetes, growing geriatric population, and increasing prevalence of blindness due to diabetes are among the key factors anticipated to bolster market growth over the forecast period.

Diabetes is amongst the leading cause of blindness in people.Blindness is caused due to leaking or rupturing of retinal blood vessels, which may be permanent or temporary in nature depending on the disease-stage.

According to the Department of Assistive and Rehabilitative Services (DARS), Texas, around 78.0% cases of diabetic retinopathy were reported in 2013 that may eventually lead to loss of vision. In addition, as per the Royal National Institute of Blind People (RNIB), diabetic retinopathy was amongst the leading causes of blindness in UK in 2017. Rising patient awareness levels and increasing healthcare expenditure are also among the factors which are likely to propel market growth.

Moreover, the increasing geriatric population in both developed and developing nations is expected to propel the diabetic retinopathy market over the forecast period. According to the Population Reference Bureau report titled "Aging in the United States”, the number of people in the U.S., aged 65 years and over were projected to increase from around 46 million in 2016 to over 98 million by 2060.

Further Key Findings From the Study Suggest:
• Non-proliferative diabetic retinopathy accounted for the largest share, by type, in 2016. Presence of large number of patients within the bracket of less than 10 years of diabetic history contributed to the large size of this segment.
• Anti-VEGF segment accounted for the largest share, by management, in 2016. High applicability of these drugs in treatment of early diagnosis and mild to moderate cases of non-proliferative DR treatment is among the prime factors leading to segmental growth.
• Asia Pacific market is expected to grow with the highest CAGR over the forecast period. Large population base in this region, high prevalence of diabetes, and rising geriatric population are likely to bolster the market.
• Major players of the market include Bayer Healthcare, Novartis AG, Regeneron Pharmaceuticals Inc., Allergan plc, ThromboGenics NV, Sirnaomics, Inc., Genentech, Glycadia Pharmaceuticals, Alimera Sciences, and Ampio Pharmaceuticals, BCN Peptides, and Kowa Group.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Diabetic Nephropathy - Pipeline Review, H2 2019

Diabetic Nephropathy - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Diabetic Nephropathy - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Nephropathy - Pipeline Review, H2 2019, provides an overview of the Diabetic ...

Contrast Induced Nephropathy - Pipeline Review, H2 2019

Contrast Induced Nephropathy - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Contrast Induced Nephropathy - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Contrast Induced Nephropathy - Pipeline Review, H2 2019, provides an overview ...

Gastric Inhibitory Polypeptide Receptor - Pipeline Review, H2 2019

Gastric Inhibitory Polypeptide Receptor - Pipeline Review, H2 2019

  • $ 3500
  • August 2019

Gastric Inhibitory Polypeptide Receptor - Pipeline Review, H2 2019SummaryGastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) pipeline Target constitutes ...

Incretion Drugs Markets in China $ 4000 October 2019


ref:plp2018

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on